No products in the cart.
Rabbit Polyclonal Anti-VHL antibody (STJ98809)
Supplier: St John’s Laboratory Ltd.
Recommended applications: IHC-P, ELISA
Recommended dilution: IHC-P 1:50-300; ELISA 1:5000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-VHL antibody.
Check alternative names for the antibodyExpand
|Elongin binding protein antibody|G7 protein antibody|HRCA 1 antibody|HRCA1 antibody|Protein G7 antibody|pVHL antibody|RCA 1 antibody|RCA1 antibody|VHL 1 antibody|VHL antibody|VHL_HUMAN antibody|VHL1 antibody|VHLH antibody|Von Hippel Lindau disease tumor suppressor antibody|von Hippel Lindau syndrome antibody|von Hippel Lindau tumor suppressor antibody|Von Hippel Lindau tumor suppressor, E3 ubiquitin protein ligase antibody|Von Hippel-Lindau disease tumor suppressor antibody|Anti-Von Hippel Lindau antibody (ab135576)
SCBT cat No:
|Catalogue No.|| |
Anti-VHL antibody detects endogenous VHL.
Synthetic peptide from human protein at AA range: 1-50.
|Recommended dilution|| |
IHC-P 1:50-300; ELISA 1:5000-20000
Anti-VHL antibody was tube-contained in PBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.
Anti-VHL antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Elongin binding protein antibody, G7 protein antibody, HRCA 1 antibody, HRCA1 antibody, Protein G7 antibody, pVHL antibody, RCA 1 antibody, RCA1 antibody, VHL 1 antibody, VHL antibody, VHL_HUMAN antibody, VHL1 antibody, VHLH antibody, Von Hippel Lindau disease tumor suppressor antibody, von Hippel Lindau syndrome antibody, von Hippel Lindau tumor suppressor antibody, Von Hippel Lindau tumor suppressor, E3 ubiquitin protein ligase antibody, Von Hippel-Lindau disease tumor suppressor antibody
|Database links|| |
|Protein function|| |
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. .
|Protein tissue specificity|| |
Expressed in the adult and fetal brain and kidney.
|Involvement in disease|| |
Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; von Hippel-Lindau disease (VHLD) [MIM:193300]: VHLD is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign neoplasms, most frequently retinal, cerebellar and spinal hemangioblastoma, renal cell carcinoma (RCC), pheochromocytoma, and pancreatic tumors. VHL type 1 is without pheochromocytoma, type 2 is with pheochromocytoma. VHL type 2 is further subdivided into types 2A (pheochromocytoma, retinal angioma, and hemangioblastomas without renal cell carcinoma and pancreatic cyst) and 2B (pheochromocytoma, retinal angioma, and hemangioblastomas with renal cell carcinoma and pancreatic cyst). . Note=The disease is caused by mutations affecting the gene represented in this entry.; Erythrocytosis, familial, 2 (ECYT2) [MIM:263400]: An autosomal recessive disorder characterized by an increase in serum red blood cell mass, hypersensitivity of erythroid progenitors to erythropoietin, increased erythropoietin serum levels, and normal oxygen affinity. Patients with ECYT2 carry a high risk for peripheral thrombosis and cerebrovascular events. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Renal cell carcinoma (RCC) [MIM:144700]: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the VHL family. The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV].
|Protein cellular localization|| |
Isoform 1: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Note=Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated. Colocalizes with ADRB2 at the cell membrane.; Isoform 3: Cytoplasm. Nucleus. Note=Equally distributed between the nucleus and the cytoplasm but not membrane-associated.
AntibodyPlus can customize Anti-VHL antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: